| Product | Target(s) | Molecular Type | Discovery | IND-Enabling | Phase I | Phase II | Phase III | BLA | Info |
|---|---|---|---|---|---|---|---|---|---|
| Immunology & Inflammation | |||||||||
| HXN-1001 | TL1A | mAb | |||||||
| HXN-1002 | TL1A/α4β7 | bsAb |
Out-lincenced to SANOFI |
||||||
| HXN-1003 | TL1A/IL23p19 | bsAb |
Out-lincenced to SANOFI |
||||||
| HXN-1011 | TSLP | Biparatopic Ab | |||||||
| HXN-1012 | TSLP/IL13 | bsAb | |||||||
| HXN-1013 | TSLP/IL33 | bsAb | |||||||
| HXN-1021 | OX40L | mAb | |||||||
| HXN-1022 | OX40L/IL31 | bsAb | |||||||
| Product | Target(s) | Molecular Type | Discovery | IND-Enabling | Phase I | Phase II | Phase III | BLA | Info |
|---|---|---|---|---|---|---|---|---|---|
| Oncology | |||||||||
| HXN-1031 | CD19/BCMA/CD3 | Trispecific TCE | |||||||
| HXN-2002 | GUCY2C/CD3 | Biparatopic TCE | |||||||
| HXN-2006 | TROP2/PDL1 | Bispecific ADC | |||||||
| HXN-2009 | DLL3/CD3 | Biparatopic TCE | |||||||
| HXN-2010 | DLL3 | Biparatopic ADC | |||||||
| HXN-2031 | PD1-IL15 | Fusion protein | |||||||